A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab

Por Lee, Sang-Kyu, Cho, Yong-Hee, Cha, Pu-Hyeon, Yoon, Jeong-Soo, Ro, Eun Ji, Jeong, Woo-Jeong, Park, Jieun, Kim, Hyuntae, Il Kim, Tae, Min, Do Sik, Han, Gyoonhee, Choi, Kang-Yell
Publicado no Exp Mol Med (2018)

KY1022, a small molecule destabilizing Ras via targeting the Wnt/β-catenin pathway, inhibits development of metastatic colorectal cancer

Por Cho, Yong-Hee, Cha, Pu-Hyeon, Kaduwal, Saluja, Park, Jong-Chan, Lee, Sang-Kyu, Yoon, Jeong-Soo, Shin, Wookjin, Kim, Hyuntae, Ro, Eun Ji, Koo, Kyung-Hwa, Park, Ki-Sook, Han, Gyoonhee, Choi, Kang-Yell
Publicado no Oncotarget (2016)